Compare BioNTech SE - ADR (BNTX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Recursion Pharmaceuticals Inc — how do they compare? BioNTech SE - ADR trades at $88.22 (market cap $21.99B), while Recursion Pharmaceuticals Inc trades at $3.77 (market cap $2.31B). The key difference: BioNTech SE - ADR is far larger — about 9.5× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold BioNTech SE - ADR for 61 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| BNTX | RXRX | |
|---|---|---|
Market Cap | $21.99B | $2.31B |
Volume | 709,977 | 22,569,716 |
Sector | Health | Health |
52-Week High | $119.34 | $5.00 |
52-Week Low | $83.89 | $2.84 |
Typical Hold Time | 61 Days | 22 Days |
Enterprise Value | $5.85B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $87.53, down 0.73% with a bearish technical signal. The company reported mixed quarterly results, with Q3 2026 beating EPS estimates but Q2 and Q4 missing. Revenue has declined from pandemic peaks to $2.87B in 2025, with net losses widening to -$1.14B. Recent news highlights site closures and clinical trial developments in cancer vaccines. The stock shows negative cash flow trends but maintains a strong cash position of $16.78B.
Despite analyst optimism (83% buy ratings, $120.33 target), fundamental challenges persist with negative margins and high P/E of 161.14. The cancer pipeline offers long-term potential, but near-term risks include clinical setbacks and declining COVID-19 revenue. Investors should weigh the high valuation against pipeline progress and cash burn.
RXRX trades at $3.83, down 4.96% in the last session, with a bullish technical signal despite negative earnings. The company shows significant revenue growth challenges with a -961.97% net income margin, though recent partnerships and AI drug discovery platform developments provide potential catalysts. Analyst consensus is mixed with 40% buy ratings amid ongoing operational losses.
Investment outlook remains speculative given deep losses and high cash burn, offset by strategic partnerships with Tempus and Roche that could drive long-term value. Key risks include prolonged unprofitability and competitive pressures in AI-driven pharma, while technical indicators suggest near-term support near $3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
